Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of BI 1819479 in Healthy Male Volunteers
NCT07065617Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI1819479 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C]-radioactivity excreted in urine up to 37 days, Fraction of [14C]-radioactivity excreted in faeces up to 37 days and 1 more. Started Aug 2025; status: terminated.
02
Drugs
BI1819479
Beyond the preview
Go deeper on NCT07065617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065617.